These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 33064670)

  • 1. Combining radiotherapy and immunotherapy in definitive treatment of head and neck squamous cell carcinoma: review of current clinical trials.
    Plavc G; Strojan P
    Radiol Oncol; 2020 Oct; 54(4):377-393. PubMed ID: 33064670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
    Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of radiation therapy-immunotherapy for head and neck cancers: Promises kept?
    Huguet F; Durand B; Atallah S; Prébet C; Richard S; Baujat B
    Cancer Radiother; 2021 Dec; 25(8):811-815. PubMed ID: 34711485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma.
    Nindra U; Hurwitz J; Forstner D; Chin V; Gallagher R; Liu J
    Cancer Med; 2023 May; 12(10):11234-11247. PubMed ID: 36934434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control "always" matter?
    Lorini L; Gili R; Salvestrini V; Morelli I; Smussi D; Petrelli F; Bonomo P; Bossi P
    Oral Oncol; 2024 May; 152():106768. PubMed ID: 38552469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancements in neoadjuvant immune checkpoint inhibitor therapy for locally advanced head and neck squamous Carcinoma: A narrative review.
    Li J; Luo Z; Jiang S; Li J
    Int Immunopharmacol; 2024 Jun; 134():112200. PubMed ID: 38744175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma.
    Ngamphaiboon N; Chairoungdua A; Dajsakdipon T; Jiarpinitnun C
    Oral Oncol; 2023 Oct; 145():106520. PubMed ID: 37467684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
    Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
    Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in head and neck squamous cell carcinoma: An updated review.
    Parmar K; Mohamed A; Vaish E; Thawani R; Cetnar J; Thein KZ
    Cancer Treat Res Commun; 2022; 33():100649. PubMed ID: 36279709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
    Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
    Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
    Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
    Front Immunol; 2021; 12():652054. PubMed ID: 34305889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
    Park JH; Chun SH; Lee YG; Chang H; Lee KW; Kim HR; Shin SH; An HJ; Lee KE; Hwang IG; Ahn MJ; Kim SB; Keam B
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3359-3369. PubMed ID: 32671504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study.
    Vienne A; Collet L; Chevalier T; Borel C; Tardy M; Huguet F; Richard S; Salas S; Saada-Bouzid E; Fayette J; Daste A
    BMC Cancer; 2023 Jul; 23(1):663. PubMed ID: 37452287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.
    Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M
    Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.
    Daste A; Larroquette M; Gibson N; Lasserre M; Domblides C
    Immunotherapy; 2024 Feb; 16(3):187-197. PubMed ID: 38126161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma.
    Specenier P; Vermorken JB
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):901-915. PubMed ID: 29999437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the efficacy and safety of different neoadjuvant immunotherapy combinations in locally advanced HNSCC: a systematic review and meta-analysis.
    Liu C; Li M; Liu X; Shi T; Wang Y; Sui C; Zhang W; Wang B
    Front Immunol; 2024; 15():1467306. PubMed ID: 39267732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists.
    Xing DT; Khor R; Gan H; Wada M; Ermongkonchai T; Ng SP
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.